PLX Protalix BioTherapeutics, Inc.

1.00
0  -4%
Previous Close 1.04
Open 1.03
Price To book 0.00
Market Cap 124.13M
Shares 124,134,000
Volume 3,022,859
Short Ratio 0.00
Av. Daily Volume 4,012,300

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
OPRX-106
Ulcerative Colitis

Latest News

  1. Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
  2. Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials
  3. Protalix Cystic Fibrosis Drug Study Results Worsen Over Time
  4. Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
  5. Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
  6. Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA
  7. Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  8. Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
  9. Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight
  10. Today's Research Report on Trending Biotech Tickers: Protalix Biotherapeutics and Stemline Therapeutics
  11. Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
  12. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
  13. Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders
  14. Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017
  15. M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix
  16. Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
  17. Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data
  18. 7 Key FDA Decisions and Catalysts Expected in January and February